New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
09:59 EDTINCYIncyte drug unlikely to benefit patients with pancreatic cancer, TheStreet says
Reference Link
News For INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 2, 2014
07:35 EDTINCYIncyte earns $60M milestone payment from Novartis related to Jakavi
Incyte (INCY) announced that it has earned a $60M milestone payment from Novartis (NVS) related to reimbursement of Jakavi in Europe. Incyte will record this amount as contract revenue in Q3, and expects to receive payment of $60M in Q4. Under the Incyte-Novartis Collaboration and License Agreement signed in 2009, Novartis received exclusive development and commercialization rights to ruxolitinib outside of the U.S. for all hematologic and oncologic indications, and sells ruxolitinib under the name Jakavi. Ruxolitinib is marketed by Incyte in the U.S. as Jakafi. The achievement of this milestone also triggers the obligation for Incyte to pay tiered, low-single digit royalties to Novartis on all future sales of Jakafi in the U.S.
September 23, 2014
13:54 EDTINCYIncyte volatility at historic low on tight six-month range
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use